Geode Capital Management LLC Makes New $185,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW)

Geode Capital Management LLC purchased a new stake in Traws Pharma, Inc. (NASDAQ:TRAW) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 20,801 shares of the company’s stock, valued at approximately $185,000. Geode Capital Management LLC owned approximately 0.57% of Traws Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Traws Pharma Price Performance

TRAW opened at $1.42 on Friday. The company has a market capitalization of $7.57 million, a price-to-earnings ratio of -0.01 and a beta of 1.59. Traws Pharma, Inc. has a 1 year low of $1.36 and a 1 year high of $19.44. The business’s 50-day moving average price is $2.26 and its two-hundred day moving average price is $4.85.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings results on Monday, March 31st. The company reported $95.66 earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.00) by $102.66. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.06 million.

Traws Pharma Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.